PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29118925-0 2017 Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. bardoxolone methyl 0-18 AKT serine/threonine kinase 1 Homo sapiens 99-102 29118925-0 2017 Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. bardoxolone methyl 20-27 AKT serine/threonine kinase 1 Homo sapiens 99-102 29118925-0 2017 Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. bardoxolone methyl 31-37 AKT serine/threonine kinase 1 Homo sapiens 99-102 29118925-9 2017 CDDO-Me caused mitochondria-, death receptor-dependent and ER stress-mediated apoptosis in K562 cells, also induced autophagy with the suppression of PI3K/Akt/mTOR signaling pathway. bardoxolone methyl 0-7 AKT serine/threonine kinase 1 Homo sapiens 155-158 22177954-0 2012 Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells. bardoxolone methyl 22-29 AKT serine/threonine kinase 1 Homo sapiens 39-42 22177954-2 2012 Present studies show that Akt plays a critical role in the response of prostate cancer cells to CDDO-Me. bardoxolone methyl 96-103 AKT serine/threonine kinase 1 Homo sapiens 26-29 26134508-4 2015 CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells. bardoxolone methyl 0-7 AKT serine/threonine kinase 1 Homo sapiens 93-96 26134508-6 2015 Dithiothreitol inhibits the interaction of CDDO-Me with Hsp90 in cells and abrogates CDDO-Me induced upregulation of Hsp70, degradation of Akt and cell proliferation inhibition. bardoxolone methyl 85-92 AKT serine/threonine kinase 1 Homo sapiens 139-142 25733817-7 2015 Furthermore, CDDO-Me induced autophagy in both Ec109 and KYSE70 cells via suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway. bardoxolone methyl 13-20 AKT serine/threonine kinase 1 Homo sapiens 172-175 23267148-7 2013 Together, these results indicate the pivotal role ROS play in the antiproliferative- and apoptosis-inducing activity of CDDO-Me in ovarian cancer cells; however, the role of ROS in the down-regulation of prosurvival AKT, mTOR, NF-kappaB and antiapoptotic BCL-2, BCL-xL, c-IAP1 and survivin warrants further investigation. bardoxolone methyl 120-127 AKT serine/threonine kinase 1 Homo sapiens 216-219 22177954-3 2012 Silencing of Akt sensitized PC-3 cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me. bardoxolone methyl 42-49 AKT serine/threonine kinase 1 Homo sapiens 13-16 22177954-1 2012 Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined. bardoxolone methyl 91-98 AKT serine/threonine kinase 1 Homo sapiens 196-199 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 28-35 AKT serine/threonine kinase 1 Homo sapiens 39-42 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 28-35 AKT serine/threonine kinase 1 Homo sapiens 127-130 22177954-1 2012 Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-kappaB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-kappaB/mTOR signaling has remained undetermined. bardoxolone methyl 91-98 AKT serine/threonine kinase 1 Homo sapiens 283-286 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 28-35 AKT serine/threonine kinase 1 Homo sapiens 127-130 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 97-104 AKT serine/threonine kinase 1 Homo sapiens 39-42 22946344-7 2012 CDDO-Me down-regulated p-Akt, p-mTOR and NF-kappaB (p65) but increased the activation of Erk1/2 and NAC blocked the modulation of these cell signaling proteins by CDDO-Me. bardoxolone methyl 0-7 AKT serine/threonine kinase 1 Homo sapiens 25-28 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 97-104 AKT serine/threonine kinase 1 Homo sapiens 127-130 22177954-4 2012 Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-kappaB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. bardoxolone methyl 97-104 AKT serine/threonine kinase 1 Homo sapiens 127-130 22177954-6 2012 Further, inhibition of p-Akt by CDDO-Me was not attributable to an increase in the activity of protein phosphatase 2A (PP2A) or PH domain/leucine-rich repeat protein phosphatase1 (PHLPP1) both of which dephosphorylate p-Akt. bardoxolone methyl 32-39 AKT serine/threonine kinase 1 Homo sapiens 25-28 22177954-7 2012 These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis. bardoxolone methyl 51-58 AKT serine/threonine kinase 1 Homo sapiens 25-28 22177954-7 2012 These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-kappaB/mTOR prosurvival signaling axis. bardoxolone methyl 51-58 AKT serine/threonine kinase 1 Homo sapiens 66-69 22110186-0 2011 Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-kappaB/mTOR signaling. bardoxolone methyl 33-40 AKT serine/threonine kinase 1 Homo sapiens 110-113 20392997-7 2010 Induction of apoptosis by CDDO-Me was associated with the inhibition of pro-survival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2, Bcl-xL, Bad and survivin. bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 85-88 22110186-6 2011 Abrogation of AKT which regulates both NF-kappaB and mTOR increased the sensitivity of tumor cells to CDDO-Me. bardoxolone methyl 102-109 AKT serine/threonine kinase 1 Homo sapiens 14-17 22110186-7 2011 Thus, these data showing strong growth-inhibitory and apoptosis-inducing activity of CDDO-Me for ovarian cancer cells through the inhibition of AKT/ NF-kappaB/mTOR signaling pathway provide basis for evaluation of CDDO-Me for ovarian cancer. bardoxolone methyl 85-92 AKT serine/threonine kinase 1 Homo sapiens 144-147 21699019-6 2011 Furthermore, induction of apoptosis by CDDO-Me was associated with the inhibition of antiapoptotic/ prosurvival Akt, mTOR and NF-kappaB signaling proteins and the inhibition of these signaling molecules was blocked by NAG. bardoxolone methyl 39-46 AKT serine/threonine kinase 1 Homo sapiens 112-115 21799944-8 2010 The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 86-89 21799944-8 2010 The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 191-194 21799944-8 2010 The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 191-194 21799944-9 2010 Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. bardoxolone methyl 92-99 AKT serine/threonine kinase 1 Homo sapiens 13-16 21799944-9 2010 Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. bardoxolone methyl 152-159 AKT serine/threonine kinase 1 Homo sapiens 13-16 21799944-9 2010 Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. bardoxolone methyl 152-159 AKT serine/threonine kinase 1 Homo sapiens 115-118 19189297-0 2009 Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. bardoxolone methyl 22-29 AKT serine/threonine kinase 1 Homo sapiens 133-136 19782051-5 2010 In addition, CDDO-Me inhibited cell survival Akt, NF-kappaB and mTOR signaling proteins. bardoxolone methyl 13-20 AKT serine/threonine kinase 1 Homo sapiens 45-48 19782051-8 2010 NAC also prevented the inhibition of constitutively active Akt, NF-kappaB and mTOR by CDDO-Me. bardoxolone methyl 86-93 AKT serine/threonine kinase 1 Homo sapiens 59-62 19189297-5 2009 The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB). bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 74-77 19189297-5 2009 The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB). bardoxolone methyl 26-33 AKT serine/threonine kinase 1 Homo sapiens 232-235 19189297-6 2009 Silencing of Akt sensitized the PC-3 cells to CDDO-Me, whereas overexpression of Akt induced resistance to CDDO-Me. bardoxolone methyl 46-53 AKT serine/threonine kinase 1 Homo sapiens 13-16 19189297-6 2009 Silencing of Akt sensitized the PC-3 cells to CDDO-Me, whereas overexpression of Akt induced resistance to CDDO-Me. bardoxolone methyl 107-114 AKT serine/threonine kinase 1 Homo sapiens 81-84 19189297-10 2009 Data also identified Akt and mTOR as molecular targets of CDDO-Me in prostate cancer cells. bardoxolone methyl 58-65 AKT serine/threonine kinase 1 Homo sapiens 21-24 17970042-0 2007 CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. bardoxolone methyl 0-7 AKT serine/threonine kinase 1 Homo sapiens 39-42 17970042-6 2007 Furthermore, CDDO-Me inhibited the levels of anti-apoptotic Akt, mTOR and NF-kappaB (p65) signaling molecules. bardoxolone methyl 13-20 AKT serine/threonine kinase 1 Homo sapiens 60-63 17361329-10 2007 Furthermore, CDDO-Me inhibited the levels of anti-apoptotic and prosurvival p-Akt, NF-kappaB (p65) and Notch1 signaling molecules. bardoxolone methyl 13-20 AKT serine/threonine kinase 1 Homo sapiens 78-81 35204223-8 2022 Furthermore, although activated in cells that survived standalone FUS, pre-sensitization with CDDO-me and/or nelfinavir suppressed both total and activated (phosphorylated) NF-kappaB and Akt protein levels. bardoxolone methyl 94-101 AKT serine/threonine kinase 1 Homo sapiens 187-190